Quick Answer
Janux Therapeutics, Inc. reported Cash and Equivalents of $52.33 million for fiscal year 2025.
Janux Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $52.33M | -87.8% |
| 2024 | $430.61M | +2142.2% |
| 2023 | $19.20M | -62.7% |
| 2022 | $51.43M | +44.5% |
| 2021 | $35.58M | +355.4% |
| 2020 | $7.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.39M | +80.9% | -7.7% |
| June 30, 2025 | $52.45M | +257.7% | -28.9% |
| March 31, 2025 | $73.74M | -65.3% | -82.9% |
| December 31, 2024 | $430.61M | +2142.2% | +1509.5% |
| September 30, 2024 | $26.75M | +56.0% | +82.5% |
| June 30, 2024 | $14.66M | -56.5% | -93.1% |
| March 31, 2024 | $212.80M | +601.0% | +1008.1% |
| December 31, 2023 | $19.20M | -62.7% | +12.0% |
- Janux Therapeutics, Inc. showed a decrease of -87.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Janux Therapeutics, Inc.’s cash and equivalents has grown by 569.8% (from $7.81 million to $52.33 million).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: